Pavel Kolkhir

Drug Survival of Omalizumab and Factors Associated With Discontinuation in Chronic Urticaria

Importance Omalizumab is a recommended second-line therapy for chronic urticaria (CU), yet clinical evidence regarding long-term drug survival and determinants of discontinuation remains limited. Understanding drug survival patterns may inform clinical decision-making and patient...